Evaluation of the efficiency of targeting of antitumor drugs: Simulation analysis based on pharmacokinetic/pharmacodynamic considerations

Journal of Drug Targeting

Volumn 3, Issue 6, 1996, Pages 443-453

  Nakai, D ^a   Fuse, E ^b   Suzuki, H ^a   Inaba, M ^c   Sugiyama, Y ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

^c CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

Antitumor drugs; AUC; MRT; Pharmacodynamic model; Targeting

Indexed keywords

ANTINEOPLASTIC AGENT;

AREA UNDER THE CURVE; ARTICLE; CELL MEMBRANE; DOSE TIME EFFECT RELATION; DRUG BINDING; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG TRANSPORT; MEAN RESIDENCE TIME; PRIORITY JOURNAL; TUMOR BLOOD FLOW;

EID: 0029778436     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/10611869609015964     Document Type: Article

References (26)

1. Bradley, G., Juranka, P.F., and Ling, V. (1988) Mechanism of multidrug resistance. Biochim. Biophys. Acta. 948, 87-128
2. Boddy, A. Aarons, L. and Petrak, K. (1989) Efficiency of drug targeting: steady state considerations using a three-compartment model, Pharm. Res. 6:367-372
3. Boddy, A. and Aarons, L. (1991) Application of a linear recirculation model to drug targeting. J. Pharmacokinet. Biopharm. 19, 355-362
4. Deonarain, M.P., Epenetos, A.A. (1994) Targeting enzymes for cancer therapy old enzymes in new roles (Review) Br. J. Cancer 70, 786-94
5. Fujita, T., Nishikawa, M., Tamaki, C., Takakura, Y., Hashida, M. and Sezaki, H. (1992) Targeted delivery of human recombinant superoxide dismutase by chemical modification with mono- and polysaccharide derivatives. J. Pharmacol. Exp. Ther. 263, 971-978
6. Fuse, E., Kobayashi, T., Inaba, M. and Sugiyama, Y. (1995) Prediction of the maximal tolerated dose (MTD) and therapeutic effect of anticancer drugs in humans: integration of pharmacokinetics with pharmacodynamics and toxicodynamics. Cancer Treat. Reviews 21, 133-157
7. Hunt, C.A., MacGregor, R.D. and Siegel, R.A. (1986) Engineering targeted in vivo drug delivery. I. The physiologocal and physicochemical principls governing opportunities and limitations. Pharm. Res. 3, 333-344
8. Kosmas, C., Linardou, H., Epenetos, A.A. (1993) Review: advances in monoclonal antibody tumor targeting. J. Drug Targeting 1, 81-91
9. Levy, G. (1987) Targeted drug delivery - some pharmacokinetic considerations. Pharm. Res. 4, 3-4
10. Molema, G. and Meijer, D.K.F. (1994) Targeting of drugs to various blood cell types using (neo-)glycoproteins, antibodies and other protein carriers. Adv. Drug Delivery Reviews 14, 25-50
11. Monsigny, M., Roche, A.C. and Midoux, P. (1989)Endogenous Lectins and Drug Targeting.: In Biological membranes in cancer cells. Ann. N. Y. Acad. Sci. 551, 399-414
12. Ozawa, S., Sugiyama, Y., Mitsuhashi, Y., Kobayashi, T. and Inaba, M. (1988) Cell killing action of cell cycle phase-nonspecific antitumor agents is dependent on cencentration-time product. Cancer Chemother. Pharmacol. 21, 185-190
13. Ozawa, S., Sugiyama, Y., Mitsuhashi, Y. and Inaba, M. (1989) Kinetic analysis of cell killing effect induced by cytosinearabinoside and cisplatin in relation to cell cycle phase spcificity in human colon cancer and Chinese hamster cells. Cancer Res. 49, 3823-3838
14. Pang, K.S. and Rowland, M. (1977) Hepatic clearance of drugs. I. Theoretical considerations of a 'well-stirred' model and 'parallel tube' model. J. Pharmacokinet. Biopharm. 5, 625-653
15. Shimoyama, M. (1975) Cytocidal action of anticancer agents:evaluation of the sensitivity of cultured animal and human cancer cells: In Comparative leukemic research 1973, leukemogenesis. University of Tokyo Press, Tokyo/Karger, Basel, pp. 711-722
16. Shimoyama, M. and Kimura, K. (1972) Quantitative clonal growth of mamalian cells:its application for quantitative study of cytocidal action of mitomycin C. Gann 63, 773-783
17. Miyauchi, S., Sugiyama, Y., Sawada, S., Morita, K., Iga, T. and Hanano, M. (1987) Kinetics of hepatic transport of 4-methylumbeliferone in rats. Analysis by multipul indicator dilution method. J. Pharmacokinet. Biopharm. 15, 25-38
18. Siegel, R.A., MacGregor, R.D., and Hunt, C.A. (1991) Comparison and critique of two models for regional drug delivery. J. Pharmacokinet. Biopharm. 19, 363-373
19. Skipper, H.E., Schabel, F.M. Jr., Mellett, L.B. Montgomery, J.A., Wilkoff, L.J., Lloyd, H.H. and Brockman, R.W. (1970) Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother. Rep 54, 431-450
20. Suzuki, M., Hori, K., Abe, I., Saito, S. and Sato, H. (1981) A new approach to cancer chemotherapy: Selective enhancement of tumor blood flow with angiotensin II. J. Natl. Cancer. Inst. 67, 663-669
21. Takakura, Y. and Hashida, H. (1995) Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs. Crit. Reviews. Oncol. Hematol. 18, 207-231
22. Terasaki, T., Iga, T., Sugiyama, Y. and Hanano, M. (1984) Pharmacokinetic study on the mechanism of tissue distribution of doxorubicin: Interorgan and interspecics variation of tissue-to-plasma partition coefficients in rats, rabbits and guinea pigs. J. Pharm. Sci. 73, 1359-1363
23. Tomlinson, E. (1983) Microsphere delivery systems for drug targeting and controlled release. Int. J. Pharm. Technol. Prod. Manuf. 4, 49-57
24. Van der Bliek A.M. and Borst, A. (1989) Multidrug resistance. Advances in Cancer Research 52, 165-203
25. Yamaoka, K., Nakagawa, T. and Uno, T. (1978) Statistical moments in pharmacokinetics. J. Pharmacokinet. Biopharm. 6, 547-558
26. Wierzba, K., Sugiyama, Y., Okudaira, K., Iga, T. and Hanano, M. (1987) Tubulin as a major determinant of tissue distribution of vincristine. J. Pharm. Sci. 76, 872-875